{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T22:58:27Z","timestamp":1781132307797,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The optimal therapy after cyclin\u2011dependent kinase 4\/6 inhibitor (CDK4\/6i) failure in hormone receptor-positive\/human epidermal growth factor receptor 2-negative (HR\u2009+\u2009\/HER2\u2009\u2212\u2009) advanced breast cancer (BC) remains undefined. In this study, we demonstrate that dalpiciclib combined with chidamide exerted synergistic antitumor effects in estrogen receptor-positive (ER\u2009+\u2009)\/HER2\u2009\u2212\u2009BC cell lines and patient-derived organoids, providing a rationale for subsequent clinical evaluation. We conducte a single\u2011arm, phase Ib, Bayesian optimal interval dose\u2011escalation study (NCT05586841) evaluating dalpiciclib plus chidamide across four groups [A, 125\u2009mg dalpiciclib mg\/d and chidamide 25\u2009mg twice a week (BIW); B, dalpiciclib 125\u2009mg\/d, chidamide 20\u2009mg BIW; C, dalpiciclib 100\u2009mg\/d, 25\u2009mg chidamide BIW; D, dalpiciclib 100\u2009mg\/d, chidamide 20\u2009mg BIW]. The primary endpoint is maximum tolerated dose (MTD), and the secondary endpoints are objective response rate (ORR), progression\u2011free survival (PFS), disease control rate and safety. Among 22 enrolled patients, dose\u2011limiting toxicities occur in 3 patients, and the MTD is identified as group C. Grade 3\u20134 adverse events include neutropenia (100%), leukopenia (64%), and thrombocytopenia (36%). The ORR is 9.1% overall and 16.7% at the MTD, with median PFS of 5.8 months overall and 12.3 months at the MTD. Patients with PIK3CA mutations have shorter mPFS [5.04 months; 95% CI: 2.0\u2212not estimable (NE)] compared to those with wild type (9.25 months; 95% CI: 1.97\u2013NE). Here we show that dalpiciclib plus chidamide has manageable safety and preliminary antitumor activity in HR\u2009+\u2009\/HER2\u2212 advanced BC following CDK4\/6i failure.<\/jats:p>","DOI":"10.1038\/s41467-026-70650-6","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T08:44:21Z","timestamp":1773996261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dalpiciclib plus chidamide in HR\u2009+\u2009\/HER2\u2212advanced breast cancer after CDK4\/6 inhibitor failure: a phase Ib trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Jinmei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuexue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4295-0173","authenticated-orcid":false,"given":"Zefei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7337-4308","authenticated-orcid":false,"given":"Xiaojie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2823-7937","authenticated-orcid":false,"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"70650_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1340764","volume":"15","author":"LQ Cao","year":"2024","unstructured":"Cao, L. Q. et al. Therapeutic evolution in HR+\/HER2- breast cancer: from targeted therapy to endocrine therapy. Front. Pharmacol. 15, 1340764 (2024).","journal-title":"Front. Pharmacol."},{"key":"70650_CR2","doi-asserted-by":"publisher","first-page":"5425","DOI":"10.3390\/curroncol30060411","volume":"30","author":"KJ Jerzak","year":"2023","unstructured":"Jerzak, K. J. et al. HR+\/HER2- advanced breast cancer treatment in the first-line setting: expert review. Curr. Oncol. 30, 5425\u20135447 (2023).","journal-title":"Curr. Oncol."},{"key":"70650_CR3","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","volume":"21","author":"WJ Gradishar","year":"2023","unstructured":"Gradishar, W. J. et al. NCCN Guidelines\u00ae Insights: Breast Cancer, Version 4.2023. J. Natl. Compr. Cancer Netw. 21, 594\u2013608 (2023).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"70650_CR4","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso, F. et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann. Oncol. 31, 1623\u20131649 (2020).","journal-title":"Ann. Oncol."},{"key":"70650_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45835-6","volume":"15","author":"J G\u00f3mez Tejeda Za\u00f1udo","year":"2024","unstructured":"G\u00f3mez Tejeda Za\u00f1udo, J. et al. Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic\/transcriptomic determinants of resistance in a phase I\/II trial. Nat. Commun. 15, 2446 (2024).","journal-title":"Nat. Commun."},{"key":"70650_CR6","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","volume":"27","author":"B Xu","year":"2021","unstructured":"Xu, B. et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat. Med. 27, 1904\u20131909 (2021).","journal-title":"Nat. Med."},{"key":"70650_CR7","doi-asserted-by":"publisher","unstructured":"Wang, T. K. et al. The synergistic effect of proanthocyanidin and HDAC inhibitor inhibit breast cancer cell growth and promote apoptosis. Int. J. Mol. Sci. 24, https:\/\/doi.org\/10.3390\/ijms241310476 (2023).","DOI":"10.3390\/ijms241310476"},{"key":"70650_CR8","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S1470-2045(19)30164-0","volume":"20","author":"Z Jiang","year":"2019","unstructured":"Jiang, Z. et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.  Lancet Oncol. 20, 806\u2013815 (2019).","journal-title":"Lancet Oncol."},{"key":"70650_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.614458","volume":"11","author":"L Cao","year":"2021","unstructured":"Cao, L. et al. Chidamide combined with doxorubicin induced p53-driven cell cycle arrest and cell apoptosis reverse multidrug resistance of breast cancer. Front. Oncol. 11, 614458 (2021).","journal-title":"Front. Oncol."},{"key":"70650_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40164-023-00383-5","volume":"12","author":"S Gu","year":"2023","unstructured":"Gu, S. et al. Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2\/c-Myc\/RCC1 axis in acute myeloid leukemia. Exp. Hematol. Oncol. 12, 23 (2023).","journal-title":"Exp. Hematol. Oncol."},{"key":"70650_CR11","doi-asserted-by":"publisher","first-page":"605","DOI":"10.21147\/j.issn.1000-9604.2018.06.05","volume":"30","author":"Q Zhang","year":"2018","unstructured":"Zhang, Q. et al. Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer. Chin. J. Cancer Res. 30, 605\u2013612 (2018).","journal-title":"Chin. J. Cancer Res."},{"key":"70650_CR12","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/emboj.2010.136","volume":"29","author":"RH Wilting","year":"2010","unstructured":"Wilting, R. H. et al. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis.  EMBO J. 29, 2586\u20132597 (2010).","journal-title":"EMBO J."},{"key":"70650_CR13","first-page":"2751","volume":"3","author":"S Subramanian","year":"2010","unstructured":"Subramanian, S., Bates, S. E., Wright, J. J., Espinoza-Delgado, I. & Piekarz, R. L. Clinical toxicities of histone deacetylase inhibitors. Pharmacology 3, 2751\u20132767 (2010).","journal-title":"Pharmacology"},{"key":"70650_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S1470-2045(23)00172-9","volume":"24","author":"P Zhang","year":"2023","unstructured":"Zhang, P. et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.  Lancet Oncol. 24, 646\u2013657 (2023).","journal-title":"Lancet Oncol."},{"key":"70650_CR15","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.22.02392","volume":"41","author":"K Kalinsky","year":"2023","unstructured":"Kalinsky, K. et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent Kinase 4\/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN Trial. J. Clin. Oncol.: 41, 4004\u20134013 (2023).","journal-title":"J. Clin. Oncol.:"},{"key":"70650_CR16","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/JCO-24-02086","volume":"43","author":"K Kalinsky","year":"2025","unstructured":"Kalinsky, K. et al. Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the phase III postmonarch trial. J. Clin. Oncol. 43, 1101\u20131112 (2025).","journal-title":"J. Clin. Oncol."},{"key":"70650_CR17","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1200\/JCO.23.01940","volume":"42","author":"EL Mayer","year":"2024","unstructured":"Mayer, E. L. et al. PACE: a randomized phase II study of fulvestrant, palbociclib, and avelumab after progression on cyclin-dependent Kinase 4\/6 inhibitor and aromatase inhibitor for hormone receptor-positive\/human epidermal growth factor receptor-negative metastatic breast cancer. J. Clin. Oncol. 42, 2050\u20132060 (2024).","journal-title":"J. Clin. Oncol."},{"key":"70650_CR18","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1200\/JCO.2023.41.16_suppl.1001","volume":"41","author":"A Llombart-Cussac","year":"2023","unstructured":"Llombart-Cussac, A. et al. Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])\/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial. J. Clin. Oncol. 41, 1001\u20131001 (2023).","journal-title":"J. Clin. Oncol."},{"key":"70650_CR19","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","volume":"392","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri, K. L. et al. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.  N. Engl. J. Med. 392, 1189\u20131202 (2025).","journal-title":"N. Engl. J. Med."},{"key":"70650_CR20","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.annonc.2023.09.3103","volume":"34","author":"S Damodaran","year":"2023","unstructured":"Damodaran, S. et al. Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+\/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Ann. Oncol. 34, 1131\u20131140 (2023).","journal-title":"Ann. Oncol."},{"key":"70650_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62664-1","volume":"14","author":"C Schagerholm","year":"2024","unstructured":"Schagerholm, C., Robertson, S., Toosi, H., Sifakis, E. G. & Hartman, J. PIK3CA mutations in endocrine-resistant breast cancer. Sci. Rep. 14, 12542 (2024).","journal-title":"Sci. Rep."},{"key":"70650_CR22","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","volume":"8","author":"B O\u2019Leary","year":"2018","unstructured":"O\u2019Leary, B. et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 Trial. Cancer Discov. 8, 1390\u20131403 (2018).","journal-title":"Cancer Discov."},{"key":"70650_CR23","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","volume":"391","author":"NC Turner","year":"2024","unstructured":"Turner, N. C. et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer.  N. Engl. J. Med. 391, 1584\u20131596 (2024).","journal-title":"N. Engl. J. Med."},{"key":"70650_CR24","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","volume":"2","author":"S Chandarlapaty","year":"2016","unstructured":"Chandarlapaty, S. et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol. 2, 1310\u20131315 (2016).","journal-title":"JAMA Oncol."},{"key":"70650_CR25","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1158\/1078-0432.CCR-20-0224","volume":"26","author":"NC Turner","year":"2020","unstructured":"Turner, N. C. et al. ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor-positive breast cancer: a combined analysis of the phase III SoFEA and EFECT Trials. Clin. Cancer Res. 26, 5172\u20135177 (2020).","journal-title":"Clin. Cancer Res."},{"key":"70650_CR26","doi-asserted-by":"crossref","unstructured":"Crucitta, S. et al. CDK4\/6 inhibitors overcome endocrine ESR1 mutation-related resistance in metastatic breast cancer patients. Cancers 15, 1306 (2023).","DOI":"10.3390\/cancers15041306"},{"key":"70650_CR27","doi-asserted-by":"publisher","first-page":"EVIDoa2300231","DOI":"10.1056\/EVIDoa2300231","volume":"3","author":"MR Lloyd","year":"2024","unstructured":"Lloyd, M. R. et al. CDK4\/6 inhibitor efficacy in ESR1-mutant metastatic breast cancer. NEJM Evid. 3, EVIDoa2300231 (2024).","journal-title":"NEJM Evid."},{"key":"70650_CR28","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1158\/1078-0432.CCR-15-0360","volume":"21","author":"SE Wardell","year":"2015","unstructured":"Wardell, S. E. et al. Efficacy of SERD\/SERM Hybrid-CDK4\/6 inhibitor combinations in models of endocrine therapy-resistant breast cancer. Clin. Cancer Res. 21, 5121\u20135130 (2015).","journal-title":"Clin. Cancer Res."},{"key":"70650_CR29","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1158\/1078-0432.CCR-24-2307","volume":"31","author":"CA Lin","year":"2025","unstructured":"Lin, C. A. et al. ESR1 Y537S and D538G mutations drive resistance to CDK4\/6 inhibitors in estrogen receptor-positive breast cancer. Clin. Cancer Res. 31, 1667\u20131675 (2025).","journal-title":"Clin. Cancer Res."},{"key":"70650_CR30","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ccell.2024.09.009","volume":"42","author":"R Kudo","year":"2024","unstructured":"Kudo, R. et al. Long-term breast cancer response to CDK4\/6 inhibition defined by TP53-mediated geroconversion. Cancer Cell 42, 1919\u20131935.e1919 (2024).","journal-title":"Cancer Cell"},{"key":"70650_CR31","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1016\/j.clbc.2021.08.007","volume":"22","author":"WD Sinclair","year":"2022","unstructured":"Sinclair, W. D. & Cui, X. The effects of HER2 on CDK4\/6 activity in breast cancer. Clin. Breast Cancer 22, e278\u2013e285 (2022).","journal-title":"Clin. Breast Cancer"},{"key":"70650_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.taap.2019.01.017","volume":"366","author":"Z Lin","year":"2019","unstructured":"Lin, Z., Zhang, X., Zhao, F. & Ru, S. Bisphenol S promotes the cell cycle progression and cell proliferation through ER\u03b1-cyclin D-CDK4\/6-pRb pathway in MCF-7 breast cancer cells. Toxicol. Appl. Pharmacol. 366, 75\u201382 (2019).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"70650_CR33","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1016\/j.molcel.2023.10.016","volume":"83","author":"L Crozier","year":"2023","unstructured":"Crozier, L. et al. CDK4\/6 inhibitor-mediated cell overgrowth triggers osmotic and replication stress to promote senescence. Mol. cell 83, 4062\u20134077.e4065 (2023).","journal-title":"Mol. cell"},{"key":"70650_CR34","doi-asserted-by":"publisher","first-page":"e533","DOI":"10.1038\/cddis.2013.61","volume":"4","author":"MC Sachweh","year":"2013","unstructured":"Sachweh, M. C., Drummond, C. J., Higgins, M., Campbell, J. & La\u00edn, S. Incompatible effects of p53 and HDAC inhibition on p21 expression and cell cycle progression. Cell Death Dis. 4, e533 (2013).","journal-title":"Cell Death Dis."},{"key":"70650_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.breast.2022.10.018","volume":"66","author":"J Zhou","year":"2022","unstructured":"Zhou, J. et al. Clinical outcomes of tucidinostat-based therapy after prior CDK4\/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer. Breast 66, 255\u2013261 (2022).","journal-title":"Breast"},{"key":"70650_CR36","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1158\/1078-0432.CCR-16-0592","volume":"22","author":"Y Yuan","year":"2016","unstructured":"Yuan, Y., Hess, K. R., Hilsenbeck, S. G. & Gilbert, M. R. Bayesian optimal interval design: a simple and well-performing design for phase I oncology trials. Clin. Cancer Res. 22, 4291\u20134301 (2016).","journal-title":"Clin. Cancer Res."},{"key":"70650_CR37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs, N. et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172, 373\u2013386.e310 (2018).","journal-title":"Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70650-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70650-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70650-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T22:17:53Z","timestamp":1781129873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70650-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70650"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70650-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zheng Pang and Yang Li are employees of Jiangsu Hengrui Pharmaceuticals, which provided dalpiciclib for this study. The company had no role in study design, data collection, analysis, interpretation, or manuscript preparation. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5177"}}